Drug intelligence / Profile preview

MT124

Development stage: Preclinical
Lead developer: Medytox
Administration: Intramuscular

Overview

MT124 is an early-stage biopharmaceutical drug candidate being developed by Medytox for the treatment of various cancers. It is currently in the discovery and preclinical phase of development. As a part of Medytox's oncology pipeline, specific details regarding its molecular target, mechanism of action, and precise modality have not been publicly disclosed by the developer. The candidate represents Medytox's strategic expansion into the biotherapeutic oncology space beyond its established botulinum toxin portfolio.

Beyond the preview

Go deeper on MT124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT124.

Explore the full profile